David S. Morris, MD, FACS

David S. Morris, MD, FACS

Urology Associates, PC

Nashville, Tennessee

David S. Morris, MD, FACS, graduated summa cum laude from Vanderbilt University and earned his doctorate from Vanderbilt University School of Medicine in Nashville, Tennessee. Dr. Morris completed his residency training at the University of Michigan in Ann Arbor, Michigan, with a special research interest in genetics that predict the aggressiveness of prostate and bladder cancers. He authored and co-authored multiple scientific papers throughout his training and has presented research findings at regional and national meetings. He helps coordinate the genitourinary cancers program at Urology Associates’ Advanced Therapeutics Center as well as the Urology Associates Clinical Trials Program.

Disclosures:

Talks by David S. Morris, MD, FACS

2025 Medicare Part D Changes: Physician’s Perspective

Mark N. Painter, CPMA, MBS, Managing Partner, Consulting LLC, CEO, PRS Urology Service Corporation, Vice President of Coding and Reimbursement Information and CEO Relative Value Studies, Inc. is joined by Neal D. Shore, MD, FACS and David S. Morris, MD, FACS to discuss the physician’s perspective on the upcoming Medicare Part D updates. They share the benefits of these changes and the possible hardships as well.

In this third part of this series, Mark briefly highlights the Medicare Part D changes, such as the reduction of the maximum out-of-pocket expenditure and the Medicare Prescription Payment Plan (MPPP) or “smoothing option”, that the first part of this series covers in more detail. Neal D. Shore, MD, FACS and David S. Morris, MD, FACS then join Mark to share their point of view as physicians on how they are planning to maneuver these changes in the best way. David S. Morris, MD, FACS discusses how he thinks these changes will give a positive outlook to a patient’s finances, for example with the smoothing option or through grants. Also, Neal D. Shore, MD, FACS shares how offices have to prepare to help patients through the process of understanding and taking advantage of these upcoming updates.

This 15-minute discussion concludes with all speakers agreeing that the financial burden on the patient is key when it comes to medications, but they are cautiously optimistic that these upcoming changes will benefit patients, although many will still rely heavily on grants and funding to get the medications they need. Both physicians share in their hope that the upcoming Medicare Part D changes will be a step in the right direction to making healthcare more accessible to all patients and a reminder: Open Enrollment begins October 15, 2024, and runs through December 7, 2024.

Read More

Doublets and Triplets: Patient Selection

David S. Morris, MD, FACS, explores the nuances of patient selection for doublet and triplet therapies in prostate cancer, providing an in-depth analysis of current strategies and emerging evidence. He begins by outlining the principles behind using doublet and triplet therapies, focusing on the rationale for combining multiple agents to enhance therapeutic efficacy and overcome resistance mechanisms.
Dr. Morris discusses the critical factors influencing patient selection. He examines the role of clinical and molecular biomarkers in guiding therapy choices, highlighting how these markers can predict response to treatment and help identify patients who are most likely to benefit from more intensive therapeutic regimens. By leveraging biomarkers, clinicians can tailor treatments to achieve the best possible outcomes while minimizing adverse effects.
He reviews key clinical trials that have investigated doublet and triplet therapies, providing a detailed analysis of their design, results, and implications for clinical practice. His analysis includes a discussion on how to balance the potential advantages of aggressive treatment with the need to manage toxicity and maintain patient quality of life.
Dr. Morris also addresses the practical aspects of implementing doublet and triplet therapies, including considerations related to dosing, administration, and monitoring. He emphasizes the importance of a multidisciplinary approach in managing patients receiving these complex regimens, involving collaboration among oncologists, urologists, and other healthcare professionals to optimize care.

Read More

Implementation of Markers in Clinical Practice

David S. Morris, MD, FACS, discusses implementation of various markers in screening, diagnosing, and treating prostate cancer in community practice. He discusses the G-Minor (Genomics in Michigan ImpactiNg Observation or Radiation) trial and a retrospective analysis of the STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trial, wherein certain markers were able to predict both metastasis-free survival and overall survival.

Read More

Advanced Prostate Cancer Clinical Trials Updates

David S. Morris, MD, FACS, of Urology Associates, PC in Nashville, Tennessee discusses advanced prostate cancer updates, including those shared recently at medical conferences including the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU) as well as several studies, namely the STAMPEDE trial, PEACE-1, ARASENS, ENZAMET, PROpel, and MAGNITUDE. Dr. Morris unpacks the takeaways, explaining that doctors should consider adding abiraterone to androgen deprivation therapy (ADT) for high-risk, non-metastatic disease; consider adding abiraterone or darolutamide for patients with mCSPC whose therapy will include using docetaxel; and consider adding poly-ADP-ribose polymerase inhibitors (PARPi) to abiraterone in patients with first-line mCRPC.

Read More

Upper Tract Urothelial Cancer: Challenges and Opportunities for Treating the Unmet Medical Need

David S. Morris, MD, FACS, discusses current methods of diagnosing and risk-stratifying upper tract urothelial cancer (UTUC), as well as the implications of disease risk on treatment decisions. He notes the unmet need for an effective kidney-sparing option for low-risk patients, and the potential for chemoablation with UGN-101 to address this need based on findings from the OLYMPUS trial.

Read More

Join the GRU Community

- Why Join? -